INCY Technical Analysis



As of date:2/26/2024
INCY stock price:60.53
INCY 50 DMA:61.25
INCY 200 DMA:60.54
INCY MACD (200-50):-0.71
INCY RSI:59.70
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)59.70
Extremely
Oversold

Also see:
INCY Market Cap History
INCY Shares Outstanding History
INCY YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree INCY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

INTA Makes Notable Cross Below Critical Moving Average
1 hour, 9 minutes ago


Lovesac (LOVE) Shares Cross Above 200 DMA
1 hour, 17 minutes ago


Arlo Technologies Breaks Above 200-Day Moving Average - Bullish for ARLO
1 hour, 19 minutes ago


EDD Makes Notable Cross Below Critical Moving Average
1 hour, 19 minutes ago


VYGR Makes Bullish Cross Above Critical Moving Average
1 hour, 19 minutes ago


WFG Crosses Above Key Moving Average Level
1 hour, 19 minutes ago


PAM Makes Notable Cross Below Critical Moving Average
1 hour, 19 minutes ago


Bullish Two Hundred Day Moving Average Cross - CARS
1 hour, 19 minutes ago


Winmark Breaks Below 200-Day Moving Average - Notable for WINA
1 hour, 20 minutes ago


Bullish Two Hundred Day Moving Average Cross - HGTY
1 hour, 20 minutes ago


Bullish Two Hundred Day Moving Average Cross - W
1 hour, 20 minutes ago


Editas Medicine Breaks Above 200-Day Moving Average - Bullish for EDIT
1 hour, 20 minutes ago


Orange (ORAN) Shares Cross Above 200 DMA
1 hour, 22 minutes ago


AES Shares Enter Oversold Territory
1 hour, 22 minutes ago


MOTI Makes Bullish Cross Above Critical Moving Average
1 hour, 22 minutes ago


More Technical Analysis News

INCY Technical AnalysisINCY RSI
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

When researching a stock like Incyte, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from INCY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for INCY stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
INCY DMAINCY MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Incyte (INCY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

IQV Technical Analysis
ISRG Technical Analysis
JNJ Technical Analysis
LH Technical Analysis
LLY Technical Analysis
MCK Technical Analysis
MDT Technical Analysis
MMM Technical Analysis
MOH Technical Analysis
MRK Technical Analysis
More Healthcare companies »

 

INCY Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2024, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.